58

DAFTAR PUSTAKA

Adisasmito, AW. dan Tumbelaka, AR. 2006, Penggunaan Antibiotik Khususnya
pada Infeksi Bakteri Gram Negatif di ICU Anak RSAB Harapan Kita, Sari
Pediatri, 8(2) : 127-134.

American College of Clinical Pharmacy, 2005, The definition of clinical
pharmacy, diakses pada 30 September 2012 <http://www.accp.com.>

American Society for Hospital-System Pharmacist. 2008, AHFS Drug Information
Handbook, ASHP Inc., Bethesda MD, USA. p. 102

Ayalew, K., Sumati, N., Yuliya, Y. and Barbara, AJ. 2003, Carbapenems in
Pediatrics, J Ther Drug Monit, 25(5) : 593-599.

Baldwin, CM., Lyseng-Williamson, KA. and Keam, SJ. 2008, Meropenem : a
review of its use in the treatment of serious bacterial infections, Drugs,
68(6) : 803-838.

BNF staff. 2011, British National Formulary 61, Pharmaceutical Press, London,
UK, p. 346.

BNFC org. 2009, British National Formulary for children, BMJ Publishing Group
Ltd., London, UK, p. 327.

Bradley, JS. 1999, Carbapenems in clinical practice : a guide to their use in
serious infection, Int J Antimicrob Agents, 11(2) : 93-100.

Brunton, L., Lazo, JS. and Parker, KL. (ed). 2006, Goodman & Gilmans The
Pharmacological Basis of Therapeutics, 11th Edition, The McGraw-Hill
Comp., chapter 42.

Byrne, S. 1995, Clinical evaluation of meropenem versus ceftazidime for
treatment of Pseudomonas spp. infection in cystic fibrosis patients, J
Antimicrob Chemother, 36 Suppl A : 135-143.

Centre for Disease Control and Prevention, 2011a, Delivering safe care for
patients : all healthcare providers play a role, Get Smart Programs, diakses
pada 29 September 2012 <http://www.cdc.gov/getsmart/healthcare/>

Centre for Disease Control and Prevention, 2011b, Resistance anywhere is
resistance everywhere, Get Smart Programs, diakses pada 29 September
2012 <http://www.cdc.gov/getsmart/healthcare/>

59

Dedic, M., Tomanovic, S. and Nikolic, L. 2005, Sensitivity to meropenem and
imipenem pseudomonas strains isolated from various patients material,
Abstract number : 1135_20 presented to 15th European Congress of
Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark,
April 2-5.

Dellinger, R.P. et al. 2012, Surviving Sepsis Campaign : International Guidelines
for Management of Severe Sepsis and Septic Shock, Critical Care Medicine
and Intensive Cara Medicine, 41(2) : 580-636.

Departemen Kesehatan Republik Indonesia, 2004, Keputusan Menteri Kesehatan
Republik Indonesia No. 1197/MENKES/SK/X/2004 tentang Standar
Pelayanan Farmasi di Rumah Sakit, Depkes RI, Jakarta, hal. 41-42.

Departemen Kesehatan Republik Indonesia, 2007, Penatalaksanaan Sepsis
Neonatorum, Depkes RI, Jakarta hal. 36-38.

Departemen Kesehatan Republik Indonesia, 2008, Tanggung Jawab Apoteker
Terhadap Keselamatan Pasien (Patient Safety ), Depkes RI, Jakarta, hal.
30.

Dipiro, J.T., Talbert, H.L., Yee, G.C. Matzke, G.R., Wells, B.G. and Posey, L.M.
2011, Pharmacotherapy a Pathophysiologic Approach, 8
th
ed, The
McGraw-Hill companies, New York, USA, chapter 116.

Dwiprahasto, I. 2005, Kebijakan untuk meminimalkan risiko resistensi bakteri di
unit perawatan intensif rumah sakit, JMPK, 8(40) : 177-181.

Edwards, SJ., Emmas, CE. and Campbell, HE. 2005, Systematic review
comparing meropenem with imipenem plus cilastatin in the treatment of
severe infection, Curr Med Res Opin, 21(5) : 785-794.

Fauziyah, S., Radji, M. dan Nurgani A. 2011, Hubungan penggunaan antibiotik
pada terapi empiris dengan kepekaan bakteri di ICU RSUP Fatmawati
Jakarta, Jurnal Farmasi Indonesia, 5(3) : 150-158.

Fleischhack, G. 2001, Meropenem versus ceftazidime as empirical monotherapy
in febrile neutropenia, J Antimicrob Chemother, 47(6) : 841-853.

Gyssens, IC., Van de Brook, PJ., Kullberg, BJ. and van der Meer, JW. 1992,
Optimizing Antimicrobial Therapy, J Antimicrob Chemother, 30 : 724-727.

Hadi, U., Duerink, DO., Lestari, ES., Nagelke, NJ., Keuter, M., Veld, DH., et al.
2008, Audit of antibiotic prescribing in two governmental teaching hospitals
in Indonesia, Clin Microb Infect, 14(7) : 698-707.

60

Hong, T., Molland, ES., Abdalhamid, B., Hanson, ND., Wang, J., Sloan, C. et al.
2005, Escherichia coli : Development of carbapenem resistance during
therapy, Clin Infect Dis, 40 : 84-86.

Hughes, WT., Armstrong, D., Bodey, GP. 2002, Guideline for the use of
antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34
: 730-751.

Januar, MG. 2010. Pengaruh Pemberian Informasi Obat Berdasarkan Beers
Criteria terhadap Pola Pemberian Obat Pada Pasien Usia Lanjut Rawat Inap
Penyakit Dalam di RSUD Prof. Dr. Margono Soekarjo Purwokerto Periode
Mei-Agustus 2010, Tesis, M.Sc., Universitas Gadjah Mada, Yogyakarta.

Kaushal, R., Bates, DW., Abramson, EL., Soukup, JR., and Goldmann, DA. 2008,
Unit-based clinical pharmacists prevention of serious medication errors in
pedatric inpatient, Am J Health-Syst Pharm, 65 : 1254-1260.

Kementerian Kesehatan RI, 2011a, Program Pencegahan dan Pengendalian
Infeksi Nosokomial merupakan Unsur Patient Safety, dipresentasikan pada
Seminar Sehari Patient Safety dan Pencegahan Pengendalian Infeksi diakses
pada 30 September 2012, <http://www.depkes.go.id/1710>

Kementerian Kesehatan RI, 2011b, Peraturan Menteri Kesehatan Republik
Indonesia Nomor 2406/MENKES/PER/XII/2011 tentang Pedoman Umum
Penggunaan Antibiotik, Jakarta, Kementerian Kesehatan RI, hal. 56-58.

Klugman, KP. and Dagan, R. 1995, Randomized comparison of meropenem with
cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis
Study Group, J Antimicrob Agents Chemother, 39(5) : 1140-1146.

Lacy, CF., Armstrong, LL. Goldman, MP. and Lance, LL. (ed). 2009, Drug
Information Handbook, 18th Edition, Lexi-Comp Inc., USA, p. 1079.

MacLaren, R., Bond, CA., Martin, SJ., Fike D. 2008, Clinical and Economic
Outcomes of Involving Pharmacist in The Direct Care of Critically Ill
Patients with Infections, Crit Care Med, 36(12) : 3269-70.

Masuda, N. and Ohya, S. 1992, Cross-Resistance to Meropenem, Cephems, and
Quinolones in Pseudomonas aeruginosa, J. Antimicroblal Agents And
Chemotherapy, 36(9) : 1847-1851.

Nicolau, DP. 2008, Carbapenem : a potent class of antibiotics, Expert Opin
Pharmacother, 9(1) : 23-37.

Odio, CM., Puig, JR. and Feris, JM. 1999, Prospective, randomized, investigator-
blinded studyof the efficacy and safety of meropenem vs. Cefotaxime
61

therapy in bacterial meningitis in children. Meropenem Meningitis Study
Group, Pediatr Infect Dis J, 18(7) : 581-590.

Ozkurt Z, Erol S, Kadanali A, Ertek M, Ozden K, Tasyaran MA. 2005, Changes
in antibiotic use, cost and consumption after an antibiotic restriction policy
applied by infectious disease specialists, Jpn J Infect Dis, 58(6) : 338-43.

Paul, M. 2006, Empirical antibiotic monotherapy for febrile neutropenia :
systematic review and meta-analysis of randomized controlled trials, J
Antimicrob Chemother, 57(2) : 176-189.

Pamela, DS. 2011, Evaluasi Kualitatif Penggunaan Antibiotika Dengan Metode
Gyssens Di Ruang Kelas 3 Infeksi Departemen ilmu Kesehatan Anak
RSCM Secara Prospektif, Tesis, M.Si., Universitas Indonesia, Jakarta.

Raveh, D., Muallem-zilcha, E., Greenberg, A., Wiener-well, Y., Schlesinger, Y.
and Yinnon, AM. 2006, Prospective drug utilization evaluation of three
broad-spectrum antimicrobials : cefepime, piperacillin-tazobactam and
meropenem, Q J Med, 99 : 397-406.

Sari, A., 2010. Pengaruh Pelayanan Informasi Obat Terhadap Potensi Interaksi
Obat Pada Pasien Rawat Inap Penyakit Dalam di RSUD Prof. Dr. Margono
Soekarjo Purwokerto Periode Mei-Agustus 2010, Tesis, M.Sc., Universitas
Gadjah Mada, Yogyakarta.

Schuler, D., 1995, Safety and efficacy of meropenem in hospitalized children :
randomised comparison with cefotaxime, alone and combined with
metronidazole or amikacin. Meropenem Paediatric Study Group. J
Antimicrob Chemother, 36 Suppl A : 99-108

Sinha, M. and Srinivasa, H. 2007, Mechanisms of resistance to carbapenems in
meropenem-resistant Acinetobacter isolates from clinical samples, Indian J
Med Microbiol, 25 : 121-5.
Sjamsiah, S. 2007, Eksistensi Farmasis di Ward. Apa dan Mengapa?,
dipresentasikan pada Seminar Nasional Farmasi Klinik : Implementasi
Pelayanan Kefarmasian dalam Tatanan Klinik & Update Farmakoterapi di
Surabaya, 16-17 Januari.

Smith, AJ., Aronson, JK and Thomas, M. 1991, Antibiotic policies in the
developing world, European Journal of Clinical Pharmacology, 41 : 85-87.

Sugiyono, 2012, Statistik untuk Penelitian, Alfabeta, Bandung, hal. 143, 376.

62

Thawani, V., Gharpure, K. And Paranjpe, BD. 2006, Antibiotics :
Pharmacoepidemiology of antibiotics, our experience, Regional Health
Forum WHO South-East Asia Region, 2(2) : 1343.

Theresia, 2011. Evaluasi Kualitatif Penggunaan Antibiotik Di Departemen Ilmu
Kesehatan Anak FKUI Rumah Sakit Cipto Mangunkusumo, Tesis, M.Si.,
Universitas Indonesia, Jakarta.

Tunkel, AR., Hartman, BJ., Kaplan, SL. 2004, Practice guideline for the
management of bacterial meningitis in children. Clin Infect Dis, 39 : 1267-
1284.

Wolter, DJ., Acquazzino, D., Goering, RV., Sammut, P., Khalat, N. And Hanson,
ND. 2008, Emergence of carbapenem resistance in Pseudomonas
aeruginosa isolate from a patient with cystic fibrosis in the absence of
carbapenem therapy, CID, 48 : 137-141.

World Health Organization, 1985, The Conference of Experts on the Rational Use
of Drugs, Nairobi, WHO, p. 35.

World Health Organization, 2008, Use of carbapenems in children, Second
Meeting of the Subcomittee of the Expert Comittee on the Selection and Use
of Essential Medicines, Geneva, WHO.

World Health Organization, 2012, Antimicrobial resistance, Media centre,
Factsheet No. 194 diakses pada 30 September 2012
<http://www.who.int/mediacentre/factsheets/fs194en/>